Recent Articles from Business Wire
The DJS Law Group announces that it is investigating claims on behalf of investors of F5, Inc. (“F5” or “the Company”) (NASDAQ: FFIV) for violations of the securities laws.
By The DJS Law Group · Via Business Wire · October 19, 2025
The DJS Law Group announces that it is investigating claims on behalf of investors of Freshpet, Inc. (“Freshpet” or “the Company”) (NASDAQ: FRPT) for violations of the securities laws.
By The DJS Law Group · Via Business Wire · October 19, 2025
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025.
By Incyte · Via Business Wire · October 19, 2025
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of F5, Inc. (“F5” or “the Company”) (NASDAQ: FFIV) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · October 19, 2025
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Freshpet, Inc. (“Freshpet” or “the Company”) (NASDAQ: FRPT) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · October 19, 2025
American Airlines, Citi and Mastercard today unveiled the Citi® / AAdvantage® Globe™ Mastercard®—a new entry in the travel credit card market that reimagines what mid-tier means with access to premium benefits. Designed to maximize the travel journey, the Citi® / AAdvantage® Globe™ Mastercard® offers four Admirals Club® Globe™ passes, each valid for 24 hours; more opportunities to earn AAdvantage® miles and Loyalty Points toward status, including a first-of-its-kind Flight Streak™ bonus; and over $750 in valuable travel and lifestyle benefits—all for an annual fee of $3501.
By Citi · Via Business Wire · October 19, 2025
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented today as part of the Presidential Symposium at the European Society for Medical Oncology 2025 Congress (ESMO 2025) in Berlin, Germany.
By Summit Therapeutics · Via Business Wire · October 19, 2025
Initial results from the dose escalation part of the first-in-human phase 1/2 trial of DS-3939 demonstrated promising clinical activity in patients with previously treated advanced solid tumors refractory to standard treatment. These data were presented today during a proffered paper session (917O) at the 2025 European Society for Medical Oncology (#ESMO25).
By Daiichi Sankyo · Via Business Wire · October 19, 2025
Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer. These data were presented today during a late-breaking proffered paper session (LBA42) at the 2025 European Society for Medical Oncology (#ESMO25) Congress.
By Daiichi Sankyo · Via Business Wire · October 19, 2025
Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead’s leadership in advancing antiviral science and its ongoing efforts to bring forward innovative solutions for people and communities most affected by infectious diseases.
By Gilead Sciences, Inc. · Via Business Wire · October 19, 2025
Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option.
By AstraZeneca · Via Business Wire · October 19, 2025
Faeth Therapeutics today announced results from the international DICE trial, a randomized phase 2 study of sapanisertib (TAK228) plus weekly paclitaxel versus paclitaxel alone in women with platinum-resistant or recurrent epithelial ovarian or fallopian tube cancer. The trial was selected for a Late-Breaking Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2025 and met its pre-ordained statistical design and there is sufficient evidence of a positive signal to justify a larger phase 3 design.
By Faeth Therapeutics · Via Business Wire · October 19, 2025
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here.
By Corcept Therapeutics Incorporated · Via Business Wire · October 19, 2025
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated efficacy and safety data from partner GenFleet Therapeutics’ Phase 1/2 monotherapy study in China of GFH375, an oral KRAS G12D (ON/OFF) inhibitor (VS-7375 outside of China) for patients with KRAS G12D mutant advanced pancreatic ductal adenocarcinoma (PDAC). Among 59 heavily pre-treated patients with advanced disease, who received two or more prior lines of therapy, an overall response rate (ORR) of 41% was achieved at the monotherapy recommended Phase 2 dose (RP2D) of 600 mg daily (QD). The updated data were featured in a late-breaking abstract for oral presentation by GenFleet Therapeutics at the European Society for Medical Oncology (ESMO) Congress 2025 on October 19, 2025, in Berlin, Germany.
By Verastem Oncology · Via Business Wire · October 19, 2025
Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) at high risk for metastasis. For the key secondary endpoint of OS, XTANDI plus leuprolide reduced the risk of death by 40.3% compared to leuprolide alone (Hazard Ratio [HR]: 0.597; 95% Confidence Interval [CI], 0.444-0.804; p=0.0006), making this the first and only androgen receptor inhibitor-based regimen to demonstrate an OS benefit in nmHSPC with high-risk BCR.1 The 8-year overall survival was 78.9% (95% CI, 73.9% to 83.1%) among patients receiving XTANDI plus leuprolide and 69.5% (95% CI, 64.0% to 74.3%) among patients taking leuprolide alone.1 A numerical improvement in OS with XTANDI as monotherapy compared to leuprolide alone (HR: 0.83 [95% CI, 0.63-1.095; p=0.1867) did not reach statistical significance.1 These data are being presented today in an oral presentation at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany and have been simultaneously published in The New England Journal of Medicine.
By Pfizer Inc. · Via Business Wire · October 19, 2025
Tubulis today announced positive early clinical data from its NAPISTAR1-01 Phase I/IIa study (NCT06303505) in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. Principal Investigator, Dr. Antonio González-Martín, Director Medical Oncology Department and Cancer Center Director at Clínica Universidad de Navarra, presented the results of Tubulis’ lead antibody-drug conjugate (ADC), TUB-040, in platinum-resistant high-grade serous ovarian cancer (PROC-HGSOC), with a focus on dose levels 1.67 – 3.3 mg/kg. This is the first clinical data to validate Tubulis’ proprietary Tubutecan technology, establishing clear proof of concept for the company’s most advanced ADC targeting NaPi2b.
By Tubulis · Via Business Wire · October 19, 2025
Positive results from the TROPION-Breast02 phase 3 trial showed DATROWAY® (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) for whom immunotherapy was not an option. These late-breaking results will be presented today during a proffered paper session (LBA21) at the 2025 European Society for Medical Oncology (#ESMO25) Congress.
By Daiichi Sankyo · Via Business Wire · October 19, 2025
Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation. In treatment-naïve patients, the median overall survival (OS) was 47.6 months (95% confidence interval [CI], 31.3, not estimable) after a median follow-up of 52.3 months. In previously treated patients, the median OS was 22.7 months (95% CI, 14.1, 32.6), after a median follow-up of 48.2 months. The four-year OS rates were 49% (95% CI, 35, 62) and 31% (95% CI, 16, 47) for treatment-naïve and previously treated patients, respectively. These data, from pre-specified secondary trial endpoints, will be presented today in an oral presentation (1849MO) at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, and have been simultaneously published in the Journal of Clinical Oncology.
By Pfizer Inc. · Via Business Wire · October 19, 2025
Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Trodelvy® (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitors. These findings will be presented today during a late-breaking oral session at the 2025 European Society for Medical Oncology (ESMO) Congress (Abstract #LBA20) and simultaneously published in The New England Journal of Medicine.
By Gilead Sciences, Inc. · Via Business Wire · October 19, 2025
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September 30, 2025, and updated 2025 full-year revenue guidance.
By Delcath Systems, Inc. · Via Business Wire · October 18, 2025
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomized Phase 2 clinical trial (CHOPIN Trial) presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, from Leiden University Medical Center’s Department of Medical Oncology at the 2025 European Society of Medical Oncology (ESMO) Annual Congress.
By Delcath Systems, Inc. · Via Business Wire · October 18, 2025
Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12 month results from the company’s Phase 1/2 CLARA trial, which evaluated the safety, efficacy and tolerability of AURN001 (neltependocel [human corneal endothelial cells] in combination with Y-27632 rho-kinase inhibitor) in patients with corneal edema secondary to corneal endothelial dysfunction. The findings were presented at Cornea Day during the American Academy of Ophthalmology (AAO) meeting in Orlando, FL.
By Aurion Biotech · Via Business Wire · October 18, 2025
Houston’s Energy Day Festival returned for its 13th year of energy, education, excitement and engagement on Saturday, Oct. 18 at Sam Houston Park in downtown Houston.
By Consumer Energy Education Foundation · Via Business Wire · October 18, 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for the treatment of patients with platinum-resistant recurrent ovarian cancer. These late-breaking data will be presented today during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2025 (Presentation #LBA3).
By Merck & Co., Inc. · Via Business Wire · October 18, 2025
Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) in patients with a high risk of disease recurrence. The trial compared ENHERTU with trastuzumab emtansine (T-DM1) as a post-neoadjuvant treatment (after surgery) in patients with HER2-positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment.
By AstraZeneca · Via Business Wire · October 18, 2025
Positive results from the DESTINY-Breast05 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) compared to trastuzumab emtansine (T-DM1) as a post-neoadjuvant treatment (after surgery) in patients with HER2 positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and a high risk of disease recurrence. Results were presented today (LBA1) alongside the results of DESTINY-Breast11 (291O) in Presidential Symposium I at the 2025 European Society for Medical Oncology (#ESMO25) Congress.
By Daiichi Sankyo · Via Business Wire · October 18, 2025
Positive results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting (before surgery) demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response (pCR) rate when compared with dose-dense doxorubicin and cyclophosphamide followed by THP (ddAC-THP) in patients with high-risk, locally advanced HER2 positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment. Results were presented today (291O) alongside the results from the DESTINY-Breast05 (LBA1) phase 3 trial during Presidential Symposium I at the 2025 European Society for Medical Oncology (#ESMO25) Congress.
By Daiichi Sankyo · Via Business Wire · October 18, 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 60% and reduced the risk of death by 50% when given before and after surgery (radical cystectomy) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for or declined cisplatin-based chemotherapy. These late-breaking data will be presented for the first time today during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2025 (Presentation #LBA2) and were selected for an official Press Briefing.
By Merck & Co., Inc. · Via Business Wire · October 18, 2025
Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting (before surgery) demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response (pCR) rate. The trial compared ENHERTU followed by THP with dose-dense doxorubicin and cyclophosphamide followed by THP (ddAC-THP) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment.
By AstraZeneca · Via Business Wire · October 18, 2025
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Snap Inc. (NYSE: SNAP) between April 29, 2025 and August 5, 2025, both dates inclusive (the “Class Period”). Snap is a technology company best known for Snapchat.
By The Rosen Law Firm, P.A. · Via Business Wire · October 18, 2025
Infrrd, a global leader in AI-driven document processing solutions, has announced the official launch of Ally, the company’s pioneering Agentic AI workforce built exclusively for the mortgage industry.
By Infrrd · Via Business Wire · October 18, 2025
University of Phoenix College of Social and Behavioral Sciences announces a new white paper, “Trauma-Informed Education – A Pathway for Relief, Retention, and Renewal,” authored by College leadership Sheila Babendir, Ed.D., LPAC; Barbara Burt, Psy.D.; Michelle Crawford-Morrison, LMFT, LPCC, NCC; Samantha E. Dutton, Ph.D., LCSW-R; Christine Karper, Ph.D., LMHC (QCS); and MaryJo Trombley, Ph.D. The paper asserts that implementing trauma-informed practices can improve outcomes for students and educators, driving retention and well-being while equipping learners with skills they can carry into the workplace.
By University of Phoenix · Via Business Wire · October 18, 2025
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany.
By Deciphera Pharmaceuticals Inc. · Via Business Wire · October 18, 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced long-term follow-up data continued to show durable benefit of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, compared to chemotherapy for patients with advanced endometrial carcinoma following at least one prior platinum-based regimen in any setting. The findings, based on five years of follow-up from the Phase 3 KEYNOTE-775/Study 309 trial evaluating KEYTRUDA plus LENVIMA versus chemotherapy (treatment of physician’s choice of doxorubicin or paclitaxel), for these patients with advanced endometrial carcinoma are being presented during a poster session at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany (Presentation #1119P).
By Merck & Co., Inc. · Via Business Wire · October 18, 2025
Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that at a median study follow-up of one year, treatment with Rina-S 100 mg/m² every 3 weeks (Q3W) resulted in a 50.0% confirmed objective response rate (ORR), including two complete responses (CR), in heavily pretreated patients with advanced endometrial cancer (EC) who had progressed following platinum-based chemotherapy and an immune checkpoint inhibitor. Additionally, at a median study follow-up of one year, 63.6% of responders (including CRs) in the 100 mg/m² cohort maintained their responses and remain on treatment. The responses were observed regardless of FRα expression levels. The updated results were presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.
By Genmab · Via Business Wire · October 18, 2025
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) originating in the lungs or thymus. These data will be presented at the 2025 European Society for Medical Oncology Congress (ESMO) during the Monday Poster Session: Neuroendocrine Tumours on October 20, 2025, from 12:00 – 12:45 p.m. CEST.
By Exelixis, Inc. · Via Business Wire · October 18, 2025
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced data from the dose escalation portion of the Phase 1/2 study of JK06, a 5T4-targeted antibody drug conjugate (ADC), in patients with unresectable locally advanced or metastatic cancer, including non-small cell lung cancer (NSCLC) and breast cancer, which is being presented at the European Society for Medical Oncology (ESMO) Congress.
By Salubris Biotherapeutics, Inc. · Via Business Wire · October 18, 2025
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA Breast Cancer study. Data showed giredestrant in combination with everolimus significantly reduced the risk of disease progression or death (progression-free survival; PFS) by 44% and 62% in the intention-to-treat (ITT) and ESR1-mutated populations, respectively, compared with standard-of-care endocrine therapy plus everolimus. The evERA study is evaluating the investigational giredestrant combination in people with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer previously treated with cyclin-dependent kinase (CDK) 4/6 inhibitor and endocrine therapy. This is the first positive head-to-head Phase III trial investigating a selective estrogen receptor degrader-containing regimen versus a standard-of-care combination. The results are being presented in an oral session at the European Society for Medical Oncology Congress 2025. Data will be shared with health authorities, with the aim of bringing this potential treatment option to people as soon as possible.
By Genentech · Via Business Wire · October 18, 2025
Please replace the release dated October 15, 2025 with the following corrected version due to multiple revisions.
By Alliant Insurance Services · Via Business Wire · October 17, 2025
Light & Wonder, Inc. (NASDAQ and ASX: LNW) (“Light & Wonder,” “L&W,” “we” or the “Company”) is providing an update on today’s ruling from the Nevada Court regarding the ongoing litigation with Aristocrat.
By Light & Wonder, Inc. · Via Business Wire · October 17, 2025
U-Haul® Company of Alaska has made all of its 11 Company facilities across the state available to provide 30 days of free self-storage and U-Box® container usage to support displaced residents after Typhoon Halong destroyed many Native communities along the western coast.
By U-Haul Holding Company · Via Business Wire · October 17, 2025
Kolibri Global Energy Inc. (the “Company” or “Kolibri“) (TSX: KEI, NASDAQ: KGEI) wishes to provide an update to certain information contained in the management information circular and related materials (the “Circular”) filed on October 15, 2025 in connection with a special meeting of shareholders (the “Meeting”) called by the Company in response to a shareholder requisition made on behalf of TFG Asset Management UK LLP, the purpose of which is to vote on altering the Notice of Articles of the Company to cap the number of common shares of the Company (“Shares”) that the Company is authorized to issue at 37,367,894 (the “Proposed Resolution”).
By Kolibri Global Energy Inc. · Via Business Wire · October 17, 2025
The Law Offices of Frank R. Cruz announces an investigation of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
By The Law Offices of Frank R. Cruz · Via Business Wire · October 17, 2025
Law Offices of Howard G. Smith announces an investigation on behalf of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors concerning the Company’s possible violations of federal securities laws.
By Law Offices of Howard G. Smith · Via Business Wire · October 17, 2025
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors concerning the Company’s possible violations of the federal securities laws.
By Glancy Prongay & Murray LLP · Via Business Wire · October 17, 2025
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Brunello Cucinelli S.p.A (OTC: BCUCY) resulting from allegations that Brunello Cucinelli may have issued materially misleading business information to the investing public.
By The Rosen Law Firm, P.A. · Via Business Wire · October 17, 2025
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 21, 2025 to file lead plaintiff applications in a securities class action lawsuit against C3.ai, Inc. (“C3” or the “Company”) (NYSE: AI), if they purchased the Company’s securities between February 26, 2025 to August 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
By Kahn Swick & Foti, LLC · Via Business Wire · October 17, 2025
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 20, 2025 to file lead plaintiff applications in a securities class action lawsuit against Snap Inc. (NYSE: SNAP), if they purchased the Company’s securities between April 29, 2025 to August 5, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.
By Kahn Swick & Foti, LLC · Via Business Wire · October 17, 2025
Asteria, the next-gen film and animation studio, today announced ALL HEART, a new animated short film written and directed by Academy Award® winners Michael Govier & Will McCormack, the filmmaking duo behind the Oscar-winning Netflix short If Anything Happens I Love You.
By Asteria · Via Business Wire · October 17, 2025
The DJS Law Group announces that it is investigating claims on behalf of investors of Grindr Inc. (“Grindr” or “the Company”) (NYSE: GRND) for potential breaches of fiduciary duty on the part of its directors and management.
By The DJS Law Group · Via Business Wire · October 17, 2025
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Brunello Cucinelli S.p.A. (“Brunello Cucinelli” or “the Company”) (OTC Markets: BCUCY) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · October 17, 2025
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of F5, Inc. (NASDAQ: FFIV) (“F5”).
By Kessler Topaz Meltzer & Check, LLP · Via Business Wire · October 17, 2025
The DJS Law Group announces that it is investigating claims on behalf of investors of Brunello Cucinelli S.p.A. (“Brunello Cucinelli” or “the Company”) (OTC Markets: BCUCY) for violations of the securities laws.
By The DJS Law Group · Via Business Wire · October 17, 2025
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Grindr Inc. (“Grindr” or “the Company”) (NYSE: GRND) for potential breaches of fiduciary duty on the part of its directors and management.
By The Schall Law Firm · Via Business Wire · October 17, 2025
Law Offices of Howard G. Smith announces an investigation on behalf of Zions Bancorporation, National Association (“Zions” or the “Company”) (NASDAQ: ZION) investors concerning the Company’s possible violations of federal securities laws.
By Law Offices of Howard G. Smith · Via Business Wire · October 17, 2025
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Zions Bancorporation, National Association (“Zions” or the “Company”) (NASDAQ: ZION) investors concerning the Company’s possible violations of the federal securities laws.
By Glancy Prongay & Murray LLP · Via Business Wire · October 17, 2025
Please replace the release with the following corrected version due to multiple revisions.
By Humankind Investments · Via Business Wire · October 17, 2025
Sensient Technologies Corporation (NYSE: SXT) will hold its earnings call and webcast to discuss 2025 third quarter results at 8:30 a.m. CDT on Friday, October 31, 2025. Investors may access the live webcast on the Company’s web site at investor.sensient.com. Alternatively, investors may join the conference call by contacting Chorus Call Inc. at (844) 492-3726 or (412) 317-1078.
By Sensient Technologies Corporation · Via Business Wire · October 17, 2025
SameDayAbortionPills—Reproductive health providers are raising concerns as patients encounter an unexpected barrier at the pharmacy counter: occasional instances of retail pharmacists declining to dispense mifepristone (Mifeprex), an FDA-approved drug used in medication abortion.
By SameDayAbortionPills · Via Business Wire · October 17, 2025
Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) announced today that its board of trustees has declared a distribution of CDN $0.2833 per unit for the month of October 2025. The distribution will be paid by Granite on November 14, 2025 to unitholders of record at the close of trading on October 31, 2025.
By Granite Real Estate Investment Trust · Via Business Wire · October 17, 2025
Calix, Inc. (NYSE: CALX) today announced that ALLO Communications has launched Smart Schools, an innovative program built on Calix SmartTown® for Education and fully integrated with the Calix Broadband Platform. Smart Schools will provide safe, secure community Wi-Fi for Lincoln Public School (LPS) students in grades 6-12 who opt into the program—promoting digital equity and extending learning beyond the classroom.
By Calix, Inc. · Via Business Wire · October 17, 2025
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Designer Brands Inc. (NYSE: DBI) resulting from allegations that Designer Brands may have issued materially misleading business information to the investing public.
By The Rosen Law Firm, P.A. · Via Business Wire · October 17, 2025
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Baxter International Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, both dates inclusive (the “Class Period”). Baxter develops, manufactures, and markets medical products.
By The Rosen Law Firm, P.A. · Via Business Wire · October 17, 2025
AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a+” (Excellent) of AMEX Assurance Company (AMEX) (headquartered in Chicago, IL). The outlook of these Credit Ratings (ratings) is stable.
By AM Best · Via Business Wire · October 17, 2025
Arctera, a global leader in data management, today announced it has been positioned as a Leader in the 2025 Gartner® Magic Quadrant™ for Digital Communications Governance and Archiving Solutions (DCGA), marking the second consecutive year the company was recognized.
By Arctera · Via Business Wire · October 17, 2025
The Chequit, located at 23 Grand Avenue in Shelter Island Heights, today announced that the property will close for the winter season on November 2, 2025, with a scheduled reopening April 2026.
By Soloviev Group · Via Business Wire · October 17, 2025
Four Corners Property Trust (NYSE:FCPT), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties (“FCPT” or the “Company”), is pleased to announce the acquisition of a Heartland Dental property for $3.3 million. The property is located in a highly trafficked corridor in Oklahoma and is corporate operated under a triple net lease with approximately four years of term remaining. The transaction was priced at a 6.9% cap rate including a near-term rent increase and exclusive of transaction costs.
By Four Corners Property Trust · Via Business Wire · October 17, 2025
The Boards of Directors of Flaherty & Crumrine Preferred and Income Fund Incorporated (NYSE: PFD), Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated (NYSE: PFO), Flaherty & Crumrine Preferred and Income Securities Fund Incorporated (NYSE: FFC), Flaherty & Crumrine Total Return Fund Incorporated (NYSE: FLC) and Flaherty & Crumrine Dynamic Preferred and Income Fund Incorporated (NYSE: DFP) today announced that they have declared per share dividends for November 2025 as detailed below:
By Flaherty & Crumrine Incorporated · Via Business Wire · October 17, 2025
Delek Logistics Partners, LP (NYSE: DKL) (“Delek Logistics”) today announced that the Partnership intends to issue a press release summarizing third quarter 2025 results before the U.S. stock market opens on Friday, November 7, 2025. A conference call to discuss these results is scheduled to begin at 11:00 a.m. CT (12:00 p.m. ET) on Friday, November 7, 2025.
By Delek Logistics Partners, LP · Via Business Wire · October 17, 2025
Delek US Holdings, Inc. (NYSE: DK) (“Delek US”) today announced that the Company intends to issue a press release summarizing third quarter 2025 results before the U.S. stock market opens on Friday, November 7, 2025. A conference call to discuss these results is scheduled to begin at 9:30 a.m. CT (10:30 a.m. ET) on Friday, November 7, 2025.
By Delek US Holdings, Inc. · Via Business Wire · October 17, 2025
RiverNorth Opportunities Fund, Inc. and RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. are each pleased to announce the declaration of preferred dividends for the fourth quarter of 2025, as detailed below.
By RiverNorth Capital Management, LLC · Via Business Wire · October 17, 2025
Intelligent power management company Eaton (NYSE:ETN) will announce third quarter 2025 earnings on Tuesday, November 4, 2025, before the opening of the New York Stock Exchange. The company will host a conference call at 11 a.m. Eastern time that day to discuss third quarter 2025 earnings results.
By Eaton · Via Business Wire · October 17, 2025
KBRA assigns a long-term rating of AA+ to the North Slope Borough, AK General Obligation Bonds, Series 2025. KBRA additionally affirms the long-term rating of AA+ for the Borough's outstanding general obligation bonds. The rating Outlook is Stable.
By Kroll Bond Rating Agency, LLC · Via Business Wire · October 17, 2025
The Law Offices of Frank R. Cruz announces an investigation of Zions Bancorporation, National Association (“Zions” or the “Company”) (NASDAQ: ZION) on behalf of investors concerning the Company’s possible violations of federal securities laws.
By The Law Offices of Frank R. Cruz · Via Business Wire · October 17, 2025
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from two Phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0.25 and 1 mg) compared with a sham procedure that mimics intravitreal (IVT) injections in people with uveitic macular edema (UME). UME is characterized by the buildup of fluid in the macula due to uveitis, an inflammatory condition of the eye, that can result in vision loss. Across both studies, the primary and secondary endpoint data support the potential for rapid improvements in vision and reductions in macular thickness (swelling in the back of the eye due to retinal fluid) with vamikibart treatment. The data were presented at the American Academy of Ophthalmology annual meeting (AAO 2025) in Orlando, FL.
By Genentech · Via Business Wire · October 17, 2025